118 related articles for article (PubMed ID: 20689403)
1. Effects of different doses, enteric-coated preparation of aspirin, and sex on urinary 11-dehydrothromboxane B2 in healthy volunteers.
Dharmasaroja PA; Sae-Lim S
Blood Coagul Fibrinolysis; 2010 Oct; 21(7):649-52. PubMed ID: 20689403
[TBL] [Abstract][Full Text] [Related]
2. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers.
Cox D; Maree AO; Dooley M; Conroy R; Byrne MF; Fitzgerald DJ
Stroke; 2006 Aug; 37(8):2153-8. PubMed ID: 16794200
[TBL] [Abstract][Full Text] [Related]
3. Effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers.
Coleman JL; Alberts MJ
Am J Cardiol; 2006 Sep; 98(6):838-41. PubMed ID: 16950199
[TBL] [Abstract][Full Text] [Related]
4. Low-dose enteric-coated aspirin as an antiplatelet preparation.
McLeod LJ; Roberts MS; Seville PR
Med J Aust; 1988 Feb; 148(4):207. PubMed ID: 3340049
[No Abstract] [Full Text] [Related]
5. Evaluation of effects of low-dose aspirin administration on urinary thromboxane metabolites in healthy dogs.
Hoh CM; Smith SA; McMichael MA; Byron JK
Am J Vet Res; 2011 Aug; 72(8):1038-45. PubMed ID: 21801060
[TBL] [Abstract][Full Text] [Related]
6. Aspirin resistance may be associated with adverse pregnancy outcomes.
Wójtowicz A; Undas A; Huras H; Musiał J; Rytlewski K; Reroń A; Wilczak M; Jach R
Neuro Endocrinol Lett; 2011; 32(3):334-9. PubMed ID: 21670728
[TBL] [Abstract][Full Text] [Related]
7. Platelet function recovery after cessation of aspirin: preliminary study of volunteers and surgical patients.
Zisman E; Erport A; Kohanovsky E; Ballagulah M; Cassel A; Quitt M; Pizov R
Eur J Anaesthesiol; 2010 Jul; 27(7):617-23. PubMed ID: 20035230
[TBL] [Abstract][Full Text] [Related]
8. Comparison of aspirin response measured by urinary 11-dehydrothromboxane B2 and VerifyNow aspirin assay in patients with ischemic stroke.
Dharmasaroja PA; Sae-Lim S
J Stroke Cerebrovasc Dis; 2014; 23(5):953-7. PubMed ID: 24126290
[TBL] [Abstract][Full Text] [Related]
9. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration.
Hedegaard SS; Hvas AM; Grove EL; Refsgaard J; Rocca B; Daví G; Kristensen SD
Thromb Res; 2009 May; 124(1):96-100. PubMed ID: 19215971
[TBL] [Abstract][Full Text] [Related]
10. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women.
Ridker PM; Hennekens CH; Tofler GH; Lipinska I; Buring JE
J Cardiovasc Risk; 1996 Apr; 3(2):209-12. PubMed ID: 8836865
[TBL] [Abstract][Full Text] [Related]
11. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2).
Blais N; Pharand C; Lordkipanidzé M; Sia YK; Merhi Y; Diodati JG
Thromb Haemost; 2009 Aug; 102(2):404-11. PubMed ID: 19652893
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of salicylate and aspirin in healthy volunteers: relevance to drug interaction on platelet function.
Cerletti C; Bonati M; del Maschio A; Galletti F; Dejana E; Tognoni G; de Gaetano G
J Lab Clin Med; 1984 Jun; 103(6):869-77. PubMed ID: 6726057
[TBL] [Abstract][Full Text] [Related]
13. Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone.
Antonino MJ; Coppolecchia R; Mahla E; Bliden KP; Tantry US; Gurbel PA
Thromb Res; 2010 Nov; 126(5):384-5. PubMed ID: 19446864
[TBL] [Abstract][Full Text] [Related]
14. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin.
Schiff M; Hochberg MC; Oldenhof J; Brune K
Curr Med Res Opin; 2009 Oct; 25(10):2471-7. PubMed ID: 19678751
[TBL] [Abstract][Full Text] [Related]
15. Effects of enteric-coated, low-dose aspirin on parameters of platelet function.
Van Hecken A; Juliano ML; Depré M; De Lepeleire I; Arnout J; Dynder A; Wildonger L; Petty KJ; Gottesdiener K; De Hoon JN
Aliment Pharmacol Ther; 2002 Sep; 16(9):1683-8. PubMed ID: 12197849
[TBL] [Abstract][Full Text] [Related]
16. Peripheral venous plasma aspirin concentrations and platelet aggregation inhibition produced by enteric-coated aspirin formulations.
Brandon RA; Emmett JA; Eadie MJ; Curran AC; Bunce IH
Thromb Haemost; 1986 Apr; 55(2):222-7. PubMed ID: 3715789
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
[TBL] [Abstract][Full Text] [Related]
18. Aspirin kinetics and inhibition of platelet thromboxane generation-relevance for a solution of the "aspirin dilemma".
Cerletti C; Latini R; Del Maschio A; Galletti F; Dejana E; de Gaetano G
Thromb Haemost; 1985 Jun; 53(3):415-8. PubMed ID: 4049312
[TBL] [Abstract][Full Text] [Related]
19. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
[TBL] [Abstract][Full Text] [Related]
20. Dose- and time-dependent antiplatelet effects of aspirin.
Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]